Tucatinib (Tukysa)
HER2-positive breast cancer Tukysa is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable or metastatic HER2-positive breast cancer following first-line chemotherapy.
Phase 3 RCT in 654 women with HER2+ metastatic breast cancer on first-line maintenance trastuzumab/pertuzumab: adding tucatinib improved PFS vs placebo (median 24.9 vs 16.3 months; HR 0.641); diarrhoea in 72.7%, 6.1% grade ≥3. RCT · phase 3 · n = 654 · J Clin Oncol · 2025
Phase III trial in 463 patients with previously treated HER2+ advanced breast cancer: tucatinib plus T-DM1 vs T-DM1 alone improved median PFS (9.5 vs 7.4 months; HR 0.76), but grade ≥3 adverse events were higher (68.8% vs 41.2%). RCT · phase 3 · n = 463 · Ann Oncol · 2025